Patents by Inventor Yumiko Kawai
Yumiko Kawai has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230235056Abstract: The present disclosure provides methods for preventing, alleviating, or treating cytokine release resulting from administration of a VEGF inhibitor or side effects resulting from the cytokine release. To prevent, alleviate, or treat cytokine release or its side effects, the disclosure also provides combination therapies that use a lymphocyte-stimulating pharmaceutical agent, represented by an anti-T cell antigen-binding molecule, with a VEGF inhibitor. Among the anti-T cell antigen-binding molecules, for example, antibodies that recruit T cells as effector cells into tumor tissues are called T cell redirecting antibodies, and are known as means for treating tumors. On the other hand, when systemic cytokine production is stimulated by binding of antibodies to T cells, it is feared that this systemic action will lead to aberrations such as CRS.Type: ApplicationFiled: June 18, 2021Publication date: July 27, 2023Inventors: Takayoshi TANAKA, Yuji SANO, Yumiko KAWAI
-
Publication number: 20220041756Abstract: By replacing the antigen-binding domain, the present inventors discovered novel polypeptide complexes that retain BiTE's strong anti-tumor activity and excellent safety properties, as well as have long half-life in blood and can damage various different target cells.Type: ApplicationFiled: July 6, 2021Publication date: February 10, 2022Inventors: Junichi Nezu, Takahiro Ishiguro, Atsushi Narita, Akihisa Sakamoto, Yumiko Kawai, Tomoyuki Igawa, Taichi Kuramochi
-
Publication number: 20210388110Abstract: The present invention provides anticancer agents comprising as an active ingredient a bispecific antibody that comprises a domain comprising a glypican 3-binding antibody variable region, a domain comprising a T cell receptor complex-binding antibody variable region, and common L chains that can enhance the affinity for the two antigens, as well as pharmaceutical compositions comprising the bispecific antibody as an active ingredient, the compositions being for use in combination with other anticancer agents. The bispecific antibodies are novel molecules which are produced with high efficiency and have strong anti-tumor activity as well as safety and excellent pharmacodynamics. The bispecific antibodies can be expected to be applied to various cancers.Type: ApplicationFiled: June 21, 2021Publication date: December 16, 2021Inventors: Yasuko KINOSHITA, Yumiko KAWAI, Toshiaki TSUNENARI, Takahiro ISHIGURO, Mika ENDO, Yuji SANO
-
Publication number: 20210230311Abstract: Novel multispecific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers.Type: ApplicationFiled: April 8, 2021Publication date: July 29, 2021Inventors: Junichi NEZU, Atsushi Narita, Takahiro Ishiguro, Mika Sakurai, Hirotake Shiraiwa, Naoka Hironiwa, Tomoyuki Igawa, Yumiko Kawai
-
Patent number: 11072666Abstract: The present invention provides anticancer agents comprising as an active ingredient a bispecific antibody that comprises a domain comprising a glypican 3-binding antibody variable region, a domain comprising a T cell receptor complex-binding antibody variable region, and common L chains that can enhance the affinity for the two antigens, as well as pharmaceutical compositions comprising the bispecific antibody as an active ingredient, the compositions being for use in combination with other anticancer agents. The bispecific antibodies are novel molecules which are produced with high efficiency and have strong anti-tumor activity as well as safety and excellent pharmacodynamics. The bispecific antibodies can be expected to be applied to various cancers.Type: GrantFiled: February 24, 2017Date of Patent: July 27, 2021Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Yasuko Kinoshita, Yumiko Kawai, Toshiaki Tsunenari, Takahiro Ishiguro, Mika Endo, Yuji Sano
-
Patent number: 11066483Abstract: By replacing the antigen-binding domain, the present inventors discovered novel polypeptide complexes that retain BiTE's strong anti-tumor activity and excellent safety properties, as well as have long half-life in blood and can damage various different target cells.Type: GrantFiled: November 30, 2011Date of Patent: July 20, 2021Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Junichi Nezu, Takahiro Ishiguro, Atsushi Narita, Akihisa Sakamoto, Yumiko Kawai, Tomoyuki Igawa, Taichi Kuramochi
-
Patent number: 11001643Abstract: Multi specific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity are provided. Since the provided molecules show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce pharmaceutical compositions for treating or preventing various cancers.Type: GrantFiled: April 26, 2018Date of Patent: May 11, 2021Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Junichi Nezu, Atsushi Narita, Takahiro Ishiguro, Mika Sakurai, Hirotake Shiraiwa, Naoka Hironiwa, Tomoyuki Igawa, Yumiko Kawai
-
Publication number: 20200123256Abstract: The present invention provides multispecific antigen-binding molecules that comprise a first antigen-binding domain having RNF43-binding activity and a second antigen-binding domain having T cell receptor complex-binding activity, uses of such multispecific antigen-binding molecules, etc. The present inventors discovered novel multispecific antigen-binding molecules with excellent cellular cytotoxicity and high stability, which comprise a first antigen-binding domain having RNF43-binding activity and a second antigen-binding domain having T cell receptor complex-binding activity. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing RNF43, it is possible to produce novel pharmaceutical compositions comprising the multispecific antigen-binding molecules for treating or preventing various cancers.Type: ApplicationFiled: May 2, 2018Publication date: April 23, 2020Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Mayumi Hoshino, Yumiko Kawai, Takahiro Ishiguro, Satoshi Aida, Yoshinao Ruike, Shu Wen Samantha Ho, Shuet Theng Lee
-
Publication number: 20200048361Abstract: The present invention provides anticancer agents comprising as an active ingredient a bispecific antibody that comprises a domain comprising a glypican 3-binding antibody variable region, a domain comprising a T cell receptor complex-binding antibody variable region, and common L chains that can enhance the affinity for the two antigens, as well as pharmaceutical compositions comprising the bispecific antibody as an active ingredient, the compositions being for use in combination with other anticancer agents. The bispecific antibodies are novel molecules which are produced with high efficiency and have strong anti-tumor activity as well as safety and excellent pharmacodynamics. The bispecific antibodies can be expected to be applied to various cancers.Type: ApplicationFiled: February 24, 2017Publication date: February 13, 2020Inventors: Yasuko KINOSHITA, Yumiko KAWAI, Toshiaki TSUNENARI, Takahiro ISHIGURO, Mika ENDO, Yuji SANO
-
Publication number: 20180244805Abstract: Novel multispecific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers.Type: ApplicationFiled: April 26, 2018Publication date: August 30, 2018Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Junichi NEZU, Atsushi NARITA, Takahiro ISHIGURO, Mika SAKURAI, Hirotake SHIRAIWA, Naoka HIRONIWA, Tomoyuki IGAWA, Yumiko KAWAI
-
Patent number: 9975966Abstract: Novel multispecific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers.Type: GrantFiled: March 23, 2017Date of Patent: May 22, 2018Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Junichi Nezu, Atsushi Narita, Takahiro Ishiguro, Mika Sakurai, Hirotake Shiraiwa, Naoka Hironiwa, Tomoyuki Igawa, Yumiko Kawai
-
Publication number: 20170267783Abstract: Novel multi specific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity, were discovered. Since the molecules of the present invention show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce novel pharmaceutical compositions for treating or preventing various cancers.Type: ApplicationFiled: March 23, 2017Publication date: September 21, 2017Applicant: Chugai Seiyaku Kabushiki KaishaInventors: Junichi NEZU, Atsushi Narita, Takahiro Ishiguro, Mika Sakurai, Hirotake Shiraiwa, Naoka Hironiwa, Tomoyuki Igawa, Yumiko Kawai
-
Patent number: 8809429Abstract: The invention provides an aqueous pigment anti-settling agent which, when added to an aqueous coating material, demonstrates excellent pigment anti-settling effect, and in particular, demonstrates excellent pigment anti-settling effect even under a high-temperature environment.Type: GrantFiled: July 29, 2011Date of Patent: August 19, 2014Assignee: Kusumoto Chemicals, Ltd.Inventors: Norifumi Azeyanagi, Makoto Ubukata, Tomohisa Ikuta, Yumiko Kawai
-
Publication number: 20140112914Abstract: By replacing the antigen-binding domain, the present inventors discovered novel polypeptide complexes that retain BiTE's strong anti-tumor activity and excellent safety properties, as well as have long half-life in blood and can damage various different target cells.Type: ApplicationFiled: November 30, 2011Publication date: April 24, 2014Applicant: CHUGAI SEIYAKU KABUSHIKI KAISHAInventors: Junichi Nezu, Takahiro Ishiguro, Atsushi Narita, Akihisa Sakamoto, Yumiko Kawai, Tomoyuki Igawa, Taichi Kuramochi
-
Publication number: 20120125235Abstract: The invention provides an aqueous pigment anti-settling agent which, when added to an aqueous coating material, demonstrates excellent pigment anti-settling effect, and in particular, demonstrates excellent pigment anti-settling effect even under a high-temperature environment.Type: ApplicationFiled: July 29, 2011Publication date: May 24, 2012Inventors: Norifumi AZEYANAGI, Makoto Ubukata, Tomohisa Ikuta, Yumiko Kawai